Spyre Therapeutics, Inc. SYRE

SYRE Company Overview

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of antibody-based therapies for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company operates within the biotechnology and pharmaceutical research industries, with an emphasis on immunology and precision-targeted biologics designed to address chronic inflammatory conditions.

The company’s primary revenue driver is research and development funding, as it does not currently generate product sales. Spyre Therapeutics is strategically positioned around a pipeline of monoclonal antibodies engineered to selectively target disease-driving pathways in the gastrointestinal tract. The company was originally founded as Aeglea BioTherapeutics in 2013 and later rebranded as Spyre Therapeutics following a strategic restructuring and pipeline redirection toward IBD-focused antibody therapeutics.